Citation Impact
Citing Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
2011
Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants
2019 StandoutScienceNobel
Differentiation Stage-Specific Requirement in Hypoxia-Inducible Factor-1α–Regulated Glycolytic Pathway during Murine B Cell Development in Bone Marrow
2009 StandoutNobel
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer
2009
Serial phenotypic, cytogenetic and molecular genetic studies in Richter's syndrome: demonstration of lymphoma development from the chronic lymphocytic leukaemia cells
1993
Stepping out of the flow: capillary extravasation in cancer metastasis
2007
CD44: From adhesion molecules to signalling regulators
2003 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Dysregulation of growth factor signaling in human hepatocellular carcinoma
2006
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
2001
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium
2002
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
The Hallmarks of Cancer
2000 Standout
Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth
2010
Mesenchymal stem cells in tumor development
2012
Osteoporosis: now and the future
2011 Standout
The neural cell adhesion molecule NCAM in multiple myeloma
1996
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Putting tumours in context
2001 Standout
Receptor activator of NF-?B ligand, macrophage inflammatory protein-1?, and the proteasome
2003
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Richter syndrome
2004
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
2009 Standout
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
2009
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Bisphosphonates in cancer therapy
2007
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro
1987
Towards whole-body imaging at the single cell level using ultra-sensitive stem cell labeling with oligo-arginine modified upconversion nanoparticles
2012
Wnts induce migration and invasion of myeloma plasma cells
2005
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Microenvironmental regulation of metastasis
2008 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
MicroRNA signatures in human cancers
2006 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Multiple myeloma: evolving genetic events and host interactions
2002
Pancreatic Cancer
2010 Standout
INTERACTION OF TUMOR AND HOST CELLS WITH ADHESION AND EXTRACELLULAR MATRIX MOLECULES IN THE DEVELOPMENT OF MULTIPLE MYELOMA
1997
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Bone metastasis: the importance of the neighbourhood
2016
β-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression
2007 StandoutNobel
Mechanisms of Bone Metastasis
2004 Standout
Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival
2001 Standout
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
The occurrence and significance of V gene mutations in B cell—Derived human malignancy
2001
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Tensional homeostasis and the malignant phenotype
2005 Standout
Novel approaches to target the microenvironment of bone metastasis
2021
Bisphosphonate conjugation for bone specific drug targeting
2018
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
Role of stromal-derived cytokines and growth factors in bone metastasis
2003
Mechanisms of implantation: strategies for successful pregnancy
2012 Standout
A crucial role for Lyn in TIMP‐1 erythroid cell survival signalling pathway
2013 StandoutNobel
The integrated stress response
2016 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium.
1998
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
2006
Upconversion Nanoparticles: Design, Nanochemistry, and Applications in Theranostics
2014 Standout
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
2009
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
A hallmark of active class switch recombination: Transcripts directed by I promoters on looped-out circular DNAs
2001 StandoutNobel
Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor RegressionIn vivo
2007
A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment
2017
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1
2007
Targeting the bone marrow microenvironment in multiple myeloma
2014
Molecular Mechanism of Class Switch Recombination: Linkage with Somatic Hypermutation
2002 StandoutNobel
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
2008
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2009
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
2000
Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome
1993
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2008
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
2006
Overexpression of the Receptor for Hyaluronan-Mediated Motility (RHAMM) Characterizes the Malignant Clone in Multiple Myeloma: Identification of Three Distinct RHAMM Variants
1999
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
1999 Standout
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss
2017
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity
2007
Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
2003
Upconversion Luminescent Materials: Advances and Applications
2014 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
2005
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium.
1998
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas
2003 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation.
1996
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
2006
Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines
1999
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
The epithelial–mesenchymal transition: new insights in signaling, development, and disease
2006 Standout
Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies.
2006
Works of Ben Van Camp being referenced
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
2013
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model
2006
Targeting the IGF‐1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival
2007
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease
2003
Homing behaviour of the malignant cell clone in multiple myeloma
1998
Evidence that the clonogenic cell in multiple myeloma originates from a pre‐switched but somatically mutated B cell
1994
Production of fibronectin and adherence to fibronectin by human myeloma cell lines
1994
The Involvement of Adhesion Molecules in the Biology of Multiple Myeloma
1993
Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells
2002
The 5T2MM Murine Model of Multiple Myeloma: Maintenance and Analysis
2005
The 5TMM series: a useful in vivo mouse model of human multiple myeloma
2000
Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma
2004
Multiple myeloma biology: lessons from the 5TMM models
2003
Upregulation of matrix metalloproteinase‐9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells
2002
Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells
1999
Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival
2003
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
2010
In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells
2000
Southern Blot Analysis in a Case of Richter's Syndrome: Evidence for a Postrearrangement Heavy Chain Gene Deletion Associated with 571 the Altered Phenotype
1991
An Improved Harvest andin VitroExpansion Protocol for Murine Bone Marrow-Derived Mesenchymal Stem Cells
2010
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
2003
The thiol-proteindisulfide oxidoreductase in human mononuclear cells of blood and bone marrow
1986
Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
2009
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
2005
Bone Marrow-Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth in Vitro and In Vivo
2011
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition
2011